Pelegrí A, Romero R, Sentí M, Nogués X, Pedro-Botet J, Rubiés-Prat J
Department of Nephrology, Quinta La Salut l'Aliança, Barcelona, Spain.
Nephrol Dial Transplant. 1992;7(7):623-6. doi: 10.1093/ndt/7.7.623.
The effect of bezafibrate, at doses of 200 mg three times weekly throughout a period of 10 weeks, on lipoprotein (a) and triglyceride-rich lipoproteins including intermediate-density lipoproteins (IDL) has been studied in 12 patients with chronic renal failure receiving haemodialysis. No side-effects were observed, and serum creatine phosphate kinase values remained within normal limits throughout the duration of the study. Serum cholesterol, triglycerides and apoprotein (apo) B significantly decreased after bezafibrate, whereas apo A-I increased significantly. Serum lipoprotein (a) decreased after bezafibrate, although differences reached no statistical significance. The very-low-density lipoproteins (VLDL) cholesterol and the VLDL triglycerides decreased from 0.93 +/- 0.45 mmol/l (Mean +/- SD) to 0.54 +/- 0.27 mmol/l (P less than 0.05) and from 1.50 +/- 0.58 mmol/l to 0.91 +/- 0.35 mmol/l (P less than 0.01) respectively. The IDL cholesterol and IDL triglycerides decreased from 0.44 +/- 0.35 mmol/l to 0.20 +/- 0.18 mmol/l (P = NS) and from 0.46 +/- 0.35 mmol/l to 0.17 +/- 0.12 mmol/l (P less than 0.05) respectively. These data, with a substantial improvement of the lipoprotein profile in patients with chronic renal failure on haemodialysis after treatment with bezafibrate, suggest a decrease in the coronary heart disease risk.
在12例接受血液透析的慢性肾衰竭患者中，研究了苯扎贝特在10周内每周三次、每次200毫克的剂量对脂蛋白（a）和富含甘油三酯的脂蛋白（包括中间密度脂蛋白，IDL）的影响。未观察到副作用，在整个研究期间血清肌酸磷酸激酶值均保持在正常范围内。苯扎贝特治疗后，血清胆固醇、甘油三酯和载脂蛋白（apo）B显著降低，而apo A-I显著升高。苯扎贝特治疗后血清脂蛋白（a）有所降低，尽管差异无统计学意义。极低密度脂蛋白（VLDL）胆固醇和VLDL甘油三酯分别从0.93±0.45毫摩尔/升（均值±标准差）降至0.54±0.27毫摩尔/升（P＜0.05），以及从1.50±0.58毫摩尔/升降至0.91±0.35毫摩尔/升（P＜0.01）。IDL胆固醇和IDL甘油三酯分别从0.44±0.35毫摩尔/升降至0.20±0.18毫摩尔/升（P=无显著性差异）和从0.46±0.35毫摩尔/升降至0.17±0.12毫摩尔/升（P＜0.05）。这些数据表明，苯扎贝特治疗后血液透析的慢性肾衰竭患者的脂蛋白谱有显著改善，提示冠心病风险降低。
